Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$42.05
Change (%) Stock is Up 0.70 (1.69%)
Volume2,087,673
Data as of 06/22/18 4:00 p.m. ET
Refresh quote
Featured Events
Corporate Presentation
Download Documentation Corporate Presentation (June 2018)
Download Documentation GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
06/15/18GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress
Data from Four Additional Posters to be Presented, Including New Pharmacokinetic Data from HOPE-KIDS 1 Study Supporting Use of Weight-based Dosing Strategy for Voxelotor Clinical Trials in Children SOUTH SAN FRANCISCO, Calif., June 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new 24-week data from patients treated with the 900 mg dose of voxelotor in the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study in adolescents ages 6 to 17 years ... 
Printer Friendly Version
06/08/18GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Research’s 12th Annual Symposium
SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts related to the voxelotor program in sickle cell disease will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 12th Annual SCD Research and Educational Symposium in Washington, D.C., taking place June 15-17, 2018. Four encore abstracts have been accepted, including three for oral presentation. Additionally, Kenneth R. ... 
Printer Friendly Version
06/05/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that, on June 1, 2018, the compensation committee of the Company’s board of directors granted three new employees options to purchase an aggregate of 11,500 shares of the Company’s common stock with a per share exercise price of $49.75, the closing trading price on the grant date, and restricted stock units for an aggregate of 7,600 shares of the Company’s common st... 
Printer Friendly Version
05/17/18GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that data supporting its voxelotor program in sickle cell disease (SCD) will be presented during the 23rd European Hematology Association (EHA) Congress in Stockholm, taking place June 14-17, 2018. A total of five abstracts have been accepted for poster presentation including 24-week data on patients treated with the 900 mg dose of voxelotor in Part B of the HOPE-KID... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.